Voyageur Pharmaceuticals Ltd Secures USD $1.9 Million Sales Contract for SmoothX 2% Barium Contrast

Biotech & MedTech, Critical Minerals & Rare Earths

May 28, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Company”) proudly announces its first international distribution agreement with a sales commitment of USD $1.9 million (CAD $2.6M), over the first three (3) years of commercialization. The agreement is with a company specializing in the sale of radiology products in Latin America. This initial agreement grants the distributor marketing and sales rights in two countries, for SmoothX 2%, a contrast medium for use in abdominal Computed Tomography (CT) diagnostic examinations.

The distributor will assume the costs and responsibility for product regulatory approvals and commercialization in the territory, allowing Voyageur to introduce SmoothX in Latin America. This marks the beginning of Voyageur’s expansion into international markets and paves the way for the introduction of its full suite of barium sulfate contrast medium products for medical imaging.  Product pricing is based on volume milestones.

Due to the highly competitive landscape of a monopolised barium contrast industry, additional contract details are confidential. The estimated contract value has been determined based on management’s expectations with respect to sales volumes during the term of the contract.

Voyageur has four additional products at late stages of development:  

  • Vision HD® 98%:high-density (98% w/w) barium sulfate powder for upper GI double-contrast radiographic examinations.  
  • Vision LD® 96%: versatile high-density (57% w/w to 156% w/w) barium sulfate powder for single contrast radiographic examinations of the upper and lower GI tract.  
  • Smooth HD® 105%: high-density (105% w/v, 58% w/w) barium sulfate suspension for upper GI esophagogram and double contrast studies 
  • Smooth LD® 60%:low-density (60% w/v) barium sulfate suspension solution for single contrast radiographic examinations of the esophagus, stomach, and small bowel. 

Voyageur remains steadfast in its commitment to providing solutions to the medical imaging market. With the impending completion of the development of these products, the Company is poised to offer a comprehensive suite of diagnostic solutions to meet the diverse needs of healthcare professionals worldwide.

Starting with its barium contrast media product line, Voyageur’s strategy is to systematically introduce a comprehensive suite of imaging products, set to diversify the medical imaging landscape in the Canadian and international markets.  Additionally, to facilitate the introduction of its innovative products, the company plans to expand into the U.S. market, leveraging the success and regulatory approvals in other countries.

For further details on Voyageur’s innovative product offerings and to secure pre-market orders, please visit our official website at

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSXV, is in development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast market, Voyageur aims to become a key player by producing its own barium, iodine, and fullerene minerals.

Voyageur’s business plan is set to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada, ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs, further expanding its revenue streams.

Voyageur is committed to sustainability and environmental stewardship. Voyageur envisions a future where carbon neutrality is the norm, and to achieve this, it is building state-of-the-art carbon-neutral infrastructure utilising the Rain Cage EDENTM system. By investing in carbon neutral energy sources and sustainable manufacturing practices, Voyageur aims to increase revenue from carbon capture to accelerate growth. Voyageur’s unwavering commitment to the environment sets it apart as a pioneer in the industry.

At the core of its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project. This project boasts exceptional grade minerals suitable for the pharmaceutical marketplace.

Voyageur’s ambitious vision is to become the first vertically integrated, carbon-neutral company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to the final production, Voyageur ensures quality and cost efficiency. With its approach, it embodies the motto of “From the Earth to the Bottle,” highlighting Voyageur’s commitment to responsible sourcing and manufacturing practices.

For Further Information:

Brent Willis, CEO,Albert Deslauriers, CFO,
[email protected], 403-923-5944[email protected]
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding “Forward-Looking” Information

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to: the realizable value to Voyageur from the sales contract; the expectation that Voyageur will obtain drug license approvals; market acceptance and sales for the suite of five new licensed products and SmoothX; the successful completion of the clinical testing for the remaining four products; the Rain Cage EDENTM technology being carbon neutral; and availability of financing. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR+ website at Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Voyageur Pharmaceuticals Ltd.

Voyageur Pharmaceuticals Ltd. (TSXV: VM), a Canadian public company trading under the symbol VM on the TSXV, is in development of barium and iodine Active Pharmaceutical Ingredients (API)…

Leave a Reply

Your email address will not be published. Required fields are marked *